Latest News

Here's everything you need to know about the electric vehicle maker's week.

One of QuantumScape's biggest allies is getting cold feet on EVs.

In the Wednesday Report, we looked at a few charts which were showing a possible short-term low that could be forming. There still needs to be a little more confirmation, but so far the possible short-term low is still holding.

How much of the tariff cost will the multi-brand sporting goods maker pass on?

Reddit’s stock price reflects the high price of influence and narrative moderation.

After opening on a lower note, Indian benchmark indices extended their downward momentum throughout the session, ending the week's first trading session in the red.

The new entity will be called Phytanix, Inc., and it will combine the two companies’ pipelines focused on stress-related and CNS disorders.

Home Depot and Lowe's earnings are on tap with eyes on inventories and guidance,

The new IMAX with Laser locations in major U.S. cities will feature advanced 70mm projection systems and enhanced visuals.

Intuit Inc (NASDAQ: INTU) to report fiscal Q3 results on May 22, expected to beat estimates with strong tax and software performance, says analyst.

As Moody's cuts the U.S. credit rating, concerns rise over the dollar's future as the global reserve currency amid debt worries.

Snowflake inked partnerships with Microsoft, OpenAI and Anthropic; This helps the company increase credibility and reach, one analyst says.

Solana (CRYPTO: SOL) dropped 5% to $161.85 on May 19 after a three-day rally to $171.72, as profit-taking followed a burst of meme-coin activity a

Health insurance company Clover Health (NASDAQ:CLOV) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates.

Home and security products company Fortune Brands (NYSE:FBIN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 6.9% year on year to $1.03 billion. Its non-GAAP profit of $0.66 per share was in line with analysts’ consensus estimates.

Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $372 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.36 per share was 12.6% above analysts’ consensus estimates.

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per share was significantly below analysts’ consensus estimates.